Gene name: | MEOX1 |
Aging type: | Accelerate |
Aging characteristic: |
Tissue type: | -- |
Cell name: | HUVEC |
Experiment: | BrdU assay//SA-β-gal activity assay//Flow cytometry |
Description: | Likewise, we observed a decrease in the proportion of S phase cells when MEOX1 or MEOX2 were expressed in HUVECs. MEOX1 had the greatest effect on cellular proliferation and MEOX2Q235E decreased the proportion of S phase cells to the same extent as wild-type MEOX2. This corresponds to an increase from 4.5% senescence to 9.8% and 10.9% senescence, when comparing untransduced cells to cells ectopically expressing MEOX1 and MEOX2, respectively. |
Target gene: | P21/WAF1//P16 |
Official symbol(s): | P21/WAF1//P16 |
R-AG-Target gene: | Activation//Activation |
Subcategory: | Unclear |
Target gene experiment: | Luciferase reporter assay//Western blot |
Target gene description: | MEOX1 and MEOX2 induced greater than two fold activation of the luciferase reporter from the 2272 bp p21CIP1/WAF1 promoter, when compared to the empty vector control .Interestingly, the DNA binding deficient MEOX1Q220E and MEOX2Q235E proteins were able to activate this luciferase reporter to a level comparable to wild-type proteins .Compared to the EGFP control, we observed a three-fold increase in p21CIP1/WAF1 mRNA levels and more than a two-fold increase in p21CIP1/WAF1 protein levels 48 hours after adenoviral delivery of p53. Likewise, expression of MEOX1 or MEOX2 resulted in significantly increased p21CIP1/WAF1 mRNA expression.Comparable to MEOX2, MEOX1 activated the expression of a luciferase reporter from the 2272 bp p21CIP1/WAF1 promoter in HEK293 cells. |
Regulatory pathway: | -- |
R-AG-Pathway: | -- |
Pathway experiment: | -- |
Pathway description: | -- |
Annotation:
Loading,please wait...